Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285054 | 0.90 | APP (0.60) | MAPTL3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL31194266 | 0.81 | MEN1 (0.57) | MAPTL3MBTL1MEN1KMT2ALMNA | |
| Acetic Acid SCHEMBL27477993 | 0.81 | KDM4E (0.52) | MAPTL3MBTL1LMNAHDAC3HDAC1 | |
| SCHEMBL14082892 | 0.79 | MEN1 (0.62) | MAPTL3MBTL1MEN1KMT2ALMNA | |
| Acetic Acid SCHEMBL27877969 | 0.77 | MAPK1 (0.71) | MEN1KMT2ALMNATDP1MAPK1 | |
| SCHEMBL403505 | 0.76 | MAPT (0.64) | MAPTMEN1KMT2ALMNAHTT | |
| Acetic Acid SCHEMBL27904062 | 0.75 | MAPK1 (0.68) | MEN1KMT2ALMNATDP1MAPK1 | |
| SCHEMBL11665726 | 0.75 | ERN1 (0.52) | MAPTL3MBTL1MEN1KMT2ALMNA | |
| Nitrobenzene SCHEMBL6689837 | 0.73 | ALDH1A1 (0.76) | L3MBTL1MEN1KMT2ALMNATDP1 | |
| Acetic Acid SCHEMBL9711149 | 0.73 | HDAC2 (0.54) | MAPTL3MBTL1LMNAHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012978-B2 | Prodrugs of CC-A1065 analogs | IMMUNOGEN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090028821-A1 | PRODRUGS OF CC-A1065 ANALOGS | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| EP-1993999-A1 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | Sanofi-Aventis (FR) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102069-A1 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | SANOFI-AVENTIS (FR) | 2007-09-13 | — | — | WO | disclosed |
| EP-1832577-A1 | Improved prodrugs of CC-1065 analogs | Sanofi-Aventis (FR) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, SENP5, CWC15 | OPRK1 3976/4885MAPT 4463/4885L3MBTL1 2253/4885 |
| US-20090028821-A1 | PRODRUGS OF CC-A1065 ANALOGS | PDIA5, CA6, STS | OPRK1 4064/4885MAPT 4480/4885L3MBTL1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.